Uncategorized
FDA accepts new drug application for AC-170 from Nicox
The FDA has accepted the new drug application for AC-170 to treat ocular itching associated with allergic conjunctivitis, according to a press release from Nicox. The FDA granted priority review and assigned a Prescription Drug User Fee Act goal date of Oct. 18, which is indicative and contingent on information to be provided by Nicox during the review period.